Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
Identifieur interne : 000E52 ( PubMed/Corpus ); précédent : 000E51; suivant : 000E53Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
Auteurs : K. Papp ; D. Thaçi ; K. Reich ; E. Riedl ; R G Langley ; J G Krueger ; A B Gottlieb ; H. Nakagawa ; E P Bowman ; A. Mehta ; Q. Li ; Y. Zhou ; R. ShamesSource :
- The British journal of dermatology [ 1365-2133 ] ; 2015.
English descriptors
- KwdEn :
- Administration, Cutaneous, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal (administration & dosage), Antibodies, Monoclonal (adverse effects), Antibodies, Monoclonal (pharmacokinetics), Antibodies, Monoclonal, Humanized (administration & dosage), Antibodies, Monoclonal, Humanized (adverse effects), Antibodies, Monoclonal, Humanized (pharmacokinetics), Dermatologic Agents (administration & dosage), Dermatologic Agents (adverse effects), Dermatologic Agents (pharmacokinetics), Double-Blind Method, Drug Administration Schedule, Female, Humans, Interleukin-23 Subunit p19 (immunology), Male, Middle Aged, Psoriasis (drug therapy), Treatment Outcome, Young Adult.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Dermatologic Agents.
- chemical , adverse effects : Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Dermatologic Agents.
- chemical , immunology : Interleukin-23 Subunit p19.
- chemical , pharmacokinetics : Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Dermatologic Agents.
- drug therapy : Psoriasis.
- Administration, Cutaneous, Adolescent, Adult, Aged, Aged, 80 and over, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Treatment Outcome, Young Adult.
Abstract
Tildrakizumab is a high-affinity, humanized, IgG1/κ, anti-interleukin (IL)-23p19 monoclonal antibody that does not bind human IL-12 or p40 is being developed for the treatment of chronic plaque psoriasis.
DOI: 10.1111/bjd.13932
PubMed: 26042589
Links to Exploration step
pubmed:26042589Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.</title><author><name sortKey="Papp, K" sort="Papp, K" uniqKey="Papp K" first="K" last="Papp">K. Papp</name><affiliation><nlm:affiliation>Probity Medical Research, 135 Union Street East, Waterloo, ON, N2J 1C4, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Thaci, D" sort="Thaci, D" uniqKey="Thaci D" first="D" last="Thaçi">D. Thaçi</name><affiliation><nlm:affiliation>Comprehensive Center for Inflammation Medicine, University Medical School Schleswig-Holstein, University of Lübeck, Lübeck, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Reich, K" sort="Reich, K" uniqKey="Reich K" first="K" last="Reich">K. Reich</name><affiliation><nlm:affiliation>SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Riedl, E" sort="Riedl, E" uniqKey="Riedl E" first="E" last="Riedl">E. Riedl</name><affiliation><nlm:affiliation>Division of General Dermatology, Department of Dermatology, Medical University of Vienna, Vienna, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Langley, R G" sort="Langley, R G" uniqKey="Langley R" first="R G" last="Langley">R G Langley</name><affiliation><nlm:affiliation>Dalhousie University, Halifax, NS, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Krueger, J G" sort="Krueger, J G" uniqKey="Krueger J" first="J G" last="Krueger">J G Krueger</name><affiliation><nlm:affiliation>Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, U.S.A.</nlm:affiliation></affiliation></author><author><name sortKey="Gottlieb, A B" sort="Gottlieb, A B" uniqKey="Gottlieb A" first="A B" last="Gottlieb">A B Gottlieb</name><affiliation><nlm:affiliation>Department of Dermatology, Tufts Medical Center, Boston, MA, U.S.A.</nlm:affiliation></affiliation></author><author><name sortKey="Nakagawa, H" sort="Nakagawa, H" uniqKey="Nakagawa H" first="H" last="Nakagawa">H. Nakagawa</name><affiliation><nlm:affiliation>Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Bowman, E P" sort="Bowman, E P" uniqKey="Bowman E" first="E P" last="Bowman">E P Bowman</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation></affiliation></author><author><name sortKey="Mehta, A" sort="Mehta, A" uniqKey="Mehta A" first="A" last="Mehta">A. Mehta</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation></affiliation></author><author><name sortKey="Li, Q" sort="Li, Q" uniqKey="Li Q" first="Q" last="Li">Q. Li</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation></affiliation></author><author><name sortKey="Zhou, Y" sort="Zhou, Y" uniqKey="Zhou Y" first="Y" last="Zhou">Y. Zhou</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation></affiliation></author><author><name sortKey="Shames, R" sort="Shames, R" uniqKey="Shames R" first="R" last="Shames">R. Shames</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26042589</idno><idno type="pmid">26042589</idno><idno type="doi">10.1111/bjd.13932</idno><idno type="wicri:Area/PubMed/Corpus">000E52</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E52</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.</title><author><name sortKey="Papp, K" sort="Papp, K" uniqKey="Papp K" first="K" last="Papp">K. Papp</name><affiliation><nlm:affiliation>Probity Medical Research, 135 Union Street East, Waterloo, ON, N2J 1C4, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Thaci, D" sort="Thaci, D" uniqKey="Thaci D" first="D" last="Thaçi">D. Thaçi</name><affiliation><nlm:affiliation>Comprehensive Center for Inflammation Medicine, University Medical School Schleswig-Holstein, University of Lübeck, Lübeck, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Reich, K" sort="Reich, K" uniqKey="Reich K" first="K" last="Reich">K. Reich</name><affiliation><nlm:affiliation>SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Riedl, E" sort="Riedl, E" uniqKey="Riedl E" first="E" last="Riedl">E. Riedl</name><affiliation><nlm:affiliation>Division of General Dermatology, Department of Dermatology, Medical University of Vienna, Vienna, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Langley, R G" sort="Langley, R G" uniqKey="Langley R" first="R G" last="Langley">R G Langley</name><affiliation><nlm:affiliation>Dalhousie University, Halifax, NS, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Krueger, J G" sort="Krueger, J G" uniqKey="Krueger J" first="J G" last="Krueger">J G Krueger</name><affiliation><nlm:affiliation>Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, U.S.A.</nlm:affiliation></affiliation></author><author><name sortKey="Gottlieb, A B" sort="Gottlieb, A B" uniqKey="Gottlieb A" first="A B" last="Gottlieb">A B Gottlieb</name><affiliation><nlm:affiliation>Department of Dermatology, Tufts Medical Center, Boston, MA, U.S.A.</nlm:affiliation></affiliation></author><author><name sortKey="Nakagawa, H" sort="Nakagawa, H" uniqKey="Nakagawa H" first="H" last="Nakagawa">H. Nakagawa</name><affiliation><nlm:affiliation>Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Bowman, E P" sort="Bowman, E P" uniqKey="Bowman E" first="E P" last="Bowman">E P Bowman</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation></affiliation></author><author><name sortKey="Mehta, A" sort="Mehta, A" uniqKey="Mehta A" first="A" last="Mehta">A. Mehta</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation></affiliation></author><author><name sortKey="Li, Q" sort="Li, Q" uniqKey="Li Q" first="Q" last="Li">Q. Li</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation></affiliation></author><author><name sortKey="Zhou, Y" sort="Zhou, Y" uniqKey="Zhou Y" first="Y" last="Zhou">Y. Zhou</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation></affiliation></author><author><name sortKey="Shames, R" sort="Shames, R" uniqKey="Shames R" first="R" last="Shames">R. Shames</name><affiliation><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation></affiliation></author></analytic><series><title level="j">The British journal of dermatology</title><idno type="eISSN">1365-2133</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Cutaneous</term><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antibodies, Monoclonal (administration & dosage)</term><term>Antibodies, Monoclonal (adverse effects)</term><term>Antibodies, Monoclonal (pharmacokinetics)</term><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antibodies, Monoclonal, Humanized (pharmacokinetics)</term><term>Dermatologic Agents (administration & dosage)</term><term>Dermatologic Agents (adverse effects)</term><term>Dermatologic Agents (pharmacokinetics)</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Interleukin-23 Subunit p19 (immunology)</term><term>Male</term><term>Middle Aged</term><term>Psoriasis (drug therapy)</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term><term>Dermatologic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term><term>Dermatologic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Interleukin-23 Subunit p19</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term><term>Dermatologic Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Psoriasis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Cutaneous</term><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Tildrakizumab is a high-affinity, humanized, IgG1/κ, anti-interleukin (IL)-23p19 monoclonal antibody that does not bind human IL-12 or p40 is being developed for the treatment of chronic plaque psoriasis.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26042589</PMID><DateCreated><Year>2015</Year><Month>10</Month><Day>29</Day></DateCreated><DateCompleted><Year>2016</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2015</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2133</ISSN><JournalIssue CitedMedium="Internet"><Volume>173</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The British journal of dermatology</Title><ISOAbbreviation>Br. J. Dermatol.</ISOAbbreviation></Journal><ArticleTitle>Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.</ArticleTitle><Pagination><MedlinePgn>930-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bjd.13932</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Tildrakizumab is a high-affinity, humanized, IgG1/κ, anti-interleukin (IL)-23p19 monoclonal antibody that does not bind human IL-12 or p40 is being developed for the treatment of chronic plaque psoriasis.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the safety and efficacy of subcutaneous tildrakizumab in patients with moderate-to-severe chronic plaque psoriasis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A three-part, randomized, double-blind, phase IIb trial was conducted in 355 adults with chronic plaque psoriasis. Participants were randomized to receive subcutaneous tildrakizumab (5, 25, 100, 200 mg) or placebo at weeks 0 and 4 (part I) and every 12 weeks thereafter until week 52 (part II). Study drug was discontinued at week 52 and participants were followed through week 72 (part III). Primary efficacy end point was Psoriasis Area and Severity Index (PASI) 75 response at week 16. Adverse events (AEs) and vital signs were monitored throughout the study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At week 16, PASI 75 responses were 33·3% (n = 14), 64·4% (n = 58), 66·3% (n = 59), 74·4% (n = 64) and 4·4% (n = 2) in the 5-, 25-, 100- and 200-mg tildrakizumab and placebo groups, respectively (P ≤ 0·001 for each tildrakizumab dose vs. placebo). PASI 75 response was generally maintained through week 52; only eight of 222 participants who achieved PASI 75 response at week 52 and continued to part III relapsed following discontinuation up to week 72. Possible drug-related serious AEs included bacterial arthritis and lymphoedema (part I), and melanoma, stroke, epiglottitis and knee infection (part II).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Tildrakizumab had treatment effects that were superior to placebo, maintained for 52 weeks of treatment, and persisted for 20 weeks after cessation. Tildrakizumab was generally safe and well tolerated. These results suggest that IL-23p19 is a key target for suppressing psoriasis.</AbstractText><CopyrightInformation>© 2015 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Papp</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Probity Medical Research, 135 Union Street East, Waterloo, ON, N2J 1C4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thaçi</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Comprehensive Center for Inflammation Medicine, University Medical School Schleswig-Holstein, University of Lübeck, Lübeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riedl</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of General Dermatology, Department of Dermatology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langley</LastName><ForeName>R G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krueger</LastName><ForeName>J G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gottlieb</LastName><ForeName>A B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Tufts Medical Center, Boston, MA, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakagawa</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowman</LastName><ForeName>E P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Q</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shames</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01225731</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Dermatol</MedlineTA><NlmUniqueID>0004041</NlmUniqueID><ISSNLinking>0007-0963</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003879">Dermatologic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053760">Interleukin-23 Subunit p19</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598434">tildrakizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Br J Dermatol. 2015 Oct;173(4):887-8</RefSource><PMID Version="1">26511822</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Br J Dermatol. 2016 Jun;174(6):1426</RefSource><PMID Version="1">27317290</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000279" MajorTopicYN="N">Administration, Cutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003879" MajorTopicYN="N">Dermatologic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053760" MajorTopicYN="N">Interleukin-23 Subunit p19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011565" MajorTopicYN="N">Psoriasis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>05</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26042589</ArticleId><ArticleId IdType="doi">10.1111/bjd.13932</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E52 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000E52 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26042589
|texte= Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26042589" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |